Please use this identifier to cite or link to this item:
https://swslhd.intersearch.com.au/swslhdjspui/handle/1/9644
Title: | Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy |
Author: | Simmons, D. Immanuel, J. Hague, W. M. Teede, H. Nolan, C. J. Peek, M. J. Flack, J. R. McLean, M. Wong, V. Hibbert, E. Kautzky-Willer, A. Harreiter, J. Backman, H. Gianatti, E. Sweeting, A. Mohan, V. Enticott, J. Cheung, N. W. |
SWSLHD Author: | Flack, Jeffrey R. |
Issue Date: | 2023 |
Journal: | New England Journal of Medicine |
Abstract: | Background Whether treatment of gestational diabetes before 20 weeks' gestation improves maternal and infant health is unclear. Methods We randomly assigned, in a 1:1 ratio, women between 4 weeks' and 19 weeks 6 days' gestation who had a risk factor for hyperglycemia and a diagnosis of gestational diabetes (World Health Organization 2013 criteria) to receive immediate treatment for gestational diabetes or deferred or no treatment, depending on the results of a repeat oral glucose-tolerance test [OGTT] at 24 to 28 weeks' gestation (control). The trial included three primary outcomes: a composite of adverse neonatal outcomes (birth at <37 weeks' gestation, birth trauma, birth weight of �4500 g, respiratory distress, phototherapy, stillbirth or neonatal death, or shoulder dystocia), pregnancy-related hypertension (preeclampsia, eclampsia, or gestational hypertension), and neonatal lean body mass. Results A total of 802 women underwent randomization; 406 were assigned to the immediate-treatment group and 396 to the control group; follow-up data were available for 793 women (98.9%). An initial OGTT was performed at a mean (�SD) gestation of 15.6�2.5 weeks. An adverse neonatal outcome event occurred in 94 of 378 women (24.9%) in the immediate-treatment group and in 113 of 370 women (30.5%) in the control group (adjusted risk difference, -5.6 percentage points; 95% confidence interval [CI], -10.1 to -1.2). Pregnancy-related hypertension occurred in 40 of 378 women (10.6%) in the immediate-treatment group and in 37 of 372 women (9.9%) in the control group (adjusted risk difference, 0.7 percentage points; 95% CI, -1.6 to 2.9). The mean neonatal lean body mass was 2.86 kg in the immediate-treatment group and 2.91 kg in the control group (adjusted mean difference, -0.04 kg; 95% CI, -0.09 to 0.02). No between-group differences were observed with respect to serious adverse events associated with screening and treatment. Conclusions Immediate treatment of gestational diabetes before 20 weeks' gestation led to a modestly lower incidence of a composite of adverse neonatal outcomes than no immediate treatment; no material differences were observed for pregnancy-related hypertension or neonatal lean body mass. ? 2023 Massachusetts Medical Society. |
ISSN: | 00284793 (ISSN) |
Digital object identifier: | 10.1056/NEJMoa2214956 |
URI: | https://swslhd.intersearch.com.au/swslhdjspui/handle/1/9644 |
Department: | Bankstown-Lidcombe Hospital, Department of Diabetes & Endocrinology |
Appears in Collections: | Bankstown-Lidcombe Hospital Liverpool Hospital |
Files in This Item:
There are no files associated with this item.
Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.